Optiver Holding B.V. Dbv Technologies S.A. Transaction History

Optiver Holding B.V.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$0.75 - $0.95 $4 - $5	6 New	6 $0
Q3 2023 Nov 13, 2023	BUY	$1.3 - $1.88 $305,938 - $442,433	235,337 Added 595.23%	274,874 $373,000
Q2 2023 Aug 10, 2023	BUY	$1.42 - $2.23 $56,142 - $88,167	39,537 New	39,537 $75,000
Q4 2022 Feb 10, 2023	BUY	$1.16 - $1.8 $97,935 - $151,968	84,427 Added 418.54%	104,599 $160,000
Q3 2022 Nov 14, 2022	BUY	$1.77 - $2.76 $35,704 - $55,674	20,172 New	20,172 $36,000
Q2 2022 Aug 10, 2022	SELL	$1.15 - $3.25 $25,842 - $73,034	-22,472 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.22 - $1.77 $693,954 - $1.01 Million	-568,815 Reduced 96.2%	22,472 $36,000
Q4 2021 Feb 14, 2022	BUY	$1.39 - $5.58 $800,763 - $3.21 Million	576,089 Added 3790.56%	591,287 $946,000
Q3 2021 Nov 15, 2021	BUY	$4.71 - $5.92 $55,714 - $70,027	11,829 Added 351.11%	15,198 $74,000
Q2 2021 Aug 16, 2021	SELL	$5.32 - $6.53 $950,253 - $1.17 Million	-178,619 Reduced 98.15%	3,369 $18,000
Q1 2021 May 14, 2021	BUY	$2.75 - $6.57 $500,467 - $1.2 Million	181,988 New	181,988 $970,000

3.2K

Ticker DBVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,776,992
Market Cap $792M
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...

Get notified when there are updates to the investment portfolio of Optiver Holding B.V., based on Form 13F filings with the SEC.

Stay updated on Optiver Holding B.V. with notifications on news.